LFMD — LifeMD, Inc.

LifeMD (LFMD) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $46.9 million, up 4% year-over-year.
• Full Year Revenue: $194.1 million, a 25% increase from 2024.
• Active Subscribers: Nearly 323,000, a 16% year-over-year increase.
• Gross Margin: 87.1% for Q4, up 570 basis points year-over-year; 85.7% for the full year, a slight decrease of 50 basis points.
• GAAP Net Income: $19 million for Q4, or $0.41 per share (includes one-time gain from WorkSimpli sale); net loss from continuing operations was $1.9 million or $0.04 per share.
• Adjusted EBITDA: $4.8 million for Q4, up from $1.1 million year-over-year; $15.3 million for the full year, compared to $3.7 million in 2024.
• Cash Position: $36.8 million with no debt.

2. Strategic Updates and Business Highlights

• Subscriber Growth: Added over 13,000 net new subscribers in Q4, the largest gain of 2025.
• Weight Management: Record patient acquisition with 700 new sign-ups per day; successful launch of oral Wegovy in collaboration with Novo Nordisk.
• Women's Health: Significant investment in this area, including the acquisition of Optimal Human Health and partnerships with renowned experts in the field.
• Men's Health: RexMD brand returned to growth, expanding offerings to include new treatments.
• Pharmacy Operations: Now licensed in all 50 states, processing approximately 20,000 prescriptions per month; 70% of fulfillment handled in-house, improving margins.
• AI Integration: Focus on deploying AI across care delivery and operations to enhance efficiency and patient outcomes.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $48 million and $49 million; adjusted EBITDA loss projected between $4 million and $5 million due to increased patient acquisition investments.
• Full Year 2026 Revenue Guidance: Anticipated between $220 million and $230 million; adjusted EBITDA expected between $12 million and $17 million.
• Long-term Growth: Targeting an annualized revenue run rate exceeding $250 million and adjusted EBITDA exceeding $25 million by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• GAAP Net Loss: Despite strong revenue growth, the company reported a net loss from continuing operations, indicating ongoing challenges in achieving profitability.
• Women's Health Launch: While there is high demand, the women's health segment is not expected to be EBITDA positive in its first year, which may impact overall profitability in the short term.
• Competitive Pressures: New entrants like Amazon and Lilly in the weight management space could pose challenges to LifeMD's market position.

5. Notable Q&A Insights

• Demand for Wegovy: Strong demand for the oral Wegovy pill has led to nearly doubled new patient acquisitions compared to previous quarters.
• Patient Economics: The revenue model for Wegovy is around $249 per month, with healthy gross margins of approximately $100 per order.
• Insurance Integration: The company is expanding its insurance coverage, which is expected to improve customer acquisition costs and retention rates.
• Marketing Strategy: LifeMD is leveraging new media partnerships and exploring employer onboarding to drive patient acquisition.
• Retention Rates: Early retention rates for new therapies are promising, particularly for the Wegovy pill, though long-term retention remains to be fully assessed.

Overall, LifeMD reported solid financial performance and strategic initiatives aimed at growth, particularly in weight management and women's health, while navigating challenges related to profitability and competition.